Sign inJoin waitlistJoin the waitlist

MR

Madhumitha Reddy

Physician · Palm Springs Urology Medical Group PC

Credentials: · · ·

History

Palm Springs Urology Medical Group PC
2025–Present

Fellowship: University of California
2017–2018
Urology
Jefferson Health Medical Education
2012–2017
Lake Erie College of Osteopathic Medicine
2008–2012
University of Texas
2004–2008

Research

Oncologic and Functional Outcomes of Radical and Partial Nephrectomy in pT3a Pathologically Upstaged Renal Cell Carcinoma: A Multi-institutional Analysis
Clinical Genitourinary Cancer · 2020 · 42 citations
Factors Associated with Compliance in Submitting 24-Hour Urine Collections in an Underserved Community
Journal of Endourology · 2017 · 22 citations
Robotic partial nephrectomy for clinical T2a renal mass is associated with improved trifecta outcome compared to open partial nephrectomy: a single surgeon comparative analysis
World Journal of Urology · 2020 · 16 citations

Ithaar Derweesh
3 papers
KY
Kendrick Yim
3 papers
Robert Uzzo
3 papers
Ryan Nasseri
3 papers · 2 as a resident
Zachary Hamilton
3 papers · 3 as a resident
AB
Aaron Bradshaw
2 papers
Ahmed Eldefrawy
2 papers · 2 as a fellow
Alexander Kutikov
2 papers
BL
Brian Lane
2 papers
Fed Ghali
2 papers · 2 as a resident
MM
Margaret Meagher
2 papers · 2 as a resident
Stephen Ryan
2 papers · 2 as a fellow

Clinical trials

A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC
Site PI · Not yet recruiting · Phase 1
UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.
2026–2029
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Site PI · Recruiting · Phase 2
CG Oncology, Inc.
2024–2027
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Site PI · Recruiting · Phase 1, Phase 2
SURGE Therapeutics
2023–2026
An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG
Site PI · Available
CG Oncology, Inc.